“showed a trend”

Although low SLCO1B3 expression showed a trend towards shorter overall survival, this correlation was not statistically significant (p = 0.2).

- 0.987), HDL-cholesterol (0.953, 95% CI; 0.911 - 0.993), LDL-cholesterol (1.021, 95% CI; 0.998 - 1.042), Fontain IV (1.761; 95% CI; 0.726 - 4.979), LEAI in all segments (1.086, 95% CI; 0.971 - 1.175), LECS in all segments (1.633, 95% CI; 1.349 - 1.977), and log CCS (14.316, 95% CI; 4.657 - 44.009) showed a trend (P < 0.20) toward an association with multivessel-CAD.

Analysis of differences in pharmacotherapy showed a trend toward more frequent use of an aldosterone antagonist in Group I (60.0% vs. 38.7%; p = 0.2), but no differences were found regarding the use of β-blockers (100% vs. 97.1%; p = 0.254) and angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers (91.1% vs. 91.4%; p = 0.96) between both groups.

Only factors that appeared to have a significant impact on the risk for complications in UC or which showed a trend with p < 0.2 in the univariate analysis were included in the multivariate analysis.

The analyses in this study showed a trend ( p = 0.201) with the lowest HOMA-IR values in the low strain groups, increasing through group to the highest level in the high strain group.

P bt O 2 -Probe Location and Outcome Patients severely disabled or dead (mRS ≥ 5) 3 months after ICH showed a trend toward lower overall P bt O 2 values (25.5 [19.7–32.8] mmHg vs. 28.8 [20.6–36.1] mmHg, p = 0.201) and a higher incidence of BTH than patients with better outcome (26% vs. 23%, p = 0.336).

Although our results showed a trend in the increased expression of CTLA-4 in the CRC tissues, this change was not statistically significant ( p = 0.202) ( Figure 3 ). 3.5.

Although not statistically significant, the muscle invasive stage (T2 or T3, n = 8) showed a trend of higher expression of Derlin-1 mRNA ( p = 0.202) and lower expression of miR-375-3p ( p = 0.839) compared with the non-muscle invasive stage (Ta or T1, n = 4).

Comparing the expression of autophagy-related genes, ELAVL1 was significantly downregulated in erastin myotubes ( p = 0.0137; Figure 2 J), which contradicts our findings in CLI patients, whereas BECN1 showed a trend of upregulation that was not statistically significant ( p = 0.2024, Figure 2 K).

14.3%, p = 0.027) and showed a trend toward higher ORR compared to RCTS (68.8% vs. 37.5%, p = 0.204).

In 9 gastric cancer cells, we compared let-7b (in 22q13) and let-7g (in 3p21) expression with the DNA copy number change of their loci and found although the P -value is not significant due the limited number of cell lines, let-7b/g expression showed a trend of positive correlation with their array-CGH results (let-7b, P = 0.205; let-7g, P = 0.088; Additional file 3 : Figure S1).

The LA group showed a trend toward LVEDV decrease compared with both the I/R+V group (1.183±0.103 vs 1.359±0.075 ml, P = 0.206) and the wortmannin-treated group (1.183±0.103 vs 1.342±0.076 ml, P = 0.251) ( Figure 4d ), however, no statistical significance was observed.

Patients in the AsEx group showed a trend toward a shorter median time to first symptom response versus patients in the LtEx group (2.3 months [95% CI, 1.8−3.3] vs 3.8 months [95% CI, 2.6−6.0]; p = .207) even though the difference was not statistically significant, whereas the proportion of patients reaching first symptom response (anytime) was higher in the AsEx group than in the LtEx group (65.5% [114/174 patients] vs 60.6% [80/132 patients]).

In patients with HIV/TB coinfection, the granulysin levels after completion of anti-TB therapy (median = 8.535 ng/ml) showed a trend to increase compared to those before therapy (median = 7.365 ng/ml) (p = 0.208), although significant difference was not found (Figure 4 A).

Catheter-related bloodstream infections showed a trend toward improvement from 5.84% to 2.27% (χ 2 =4.544, P=0.208).

At the same time, SMAD4 alt patients showed a trend towards longer OS when treated with GemErlo compared to gemcitabine alone without reaching significance (log rank: DFS: p = 0.209, OS: p = 0.056).

As opposed to the biased model, here, TM showed a trend of higher prediction probability than CW in Sample B (CW vs TM: t = − 1.27, p = 0.2093, Cohen ́s d = − 0.36; Sample A: t = 0–0.47, p = 0.6425, Cohen ́s d = − 0.12;).

Conversely, MRG mutations showed a trend toward mutual exclusivity with recurrent alterations in CSF3R , JAK3 , ASXL2 ( p = 0.210, p = 0.350 and p = 0.587).

Although not significant, the enhanced group showed a trend toward reduced need for additional sedation (3.1% vs 7.7%, P = 0.21), suggesting better overall tolerability of the enhanced preparation protocol (Table 7 ).

Chidamide-treated females showed a trend towards improved glucose tolerance ( t (8) = 1.38, p = 0.21), but this did not reach significance ( Figure 1 A).

18 The experimental arm showed a trend towards longer mOS (19.4 versus 8.9 months for FOLFIRI and placebo, one sided p = 0.21).

In patients undergoing complex or noncomplex PCI, there was no significant difference between treatment groups, however, both subgroups showed a trend toward a reduction of major bleeding in the short‐term DAPT followed by ticagrelor monotherapy group (RR 0.62, 95% CI, 0.30–1.30, P = 0.21, I 2 = 72%; Figure 3d and RR 0.74, 95% CI, 0.48–1.14, P = 0.17, I 2 = 54%, respectively; Figure 3d ).

Arterioles in the skin also showed a trend towards differences in occlusion ratios, yet these results did not reach statistical significance ( p = 0.21 and 0.12) ( Fig 4 ).

Responses to noxious or innocuous mechanical stimulation showed a trend toward reduced sensitivity that did not reach statistical significance (pin-prick response score: 89% ± 3% versus 83% ± 3%, for control versus hM3Dq mice, p = 0.21 unpaired t test; von Frey test threshold: 3.9 ± 0.2 g versus 4.2 ± 0.2 g, p = 0.22; brush test response score: 91% ± 3% versus 81% ± 5%, p = 0.13).

BASDAI score showed a trend of high in disease activity was observed between patients with and without uveitis (MD 0.11; 95% CI − 0.06 to 0.28, p = 0.21, I 2 = 76%; Table 3 ; Fig. 2 ).